Asset Details
Do you wish to reserve the book?
The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis
Do you wish to request the book?
The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis
2023
Overview
The increasing incidence of drug resistance in
Mycobacterium tuberculosis
has diminished the efficacy of almost all available antibiotics, complicating efforts to combat the spread of this global health burden. Alongside the development of new drugs, optimised drug combinations are needed to improve treatment success and prevent the further spread of antibiotic resistance. Typically, antibiotic resistance leads to reduced sensitivity, yet in some cases the evolution of drug resistance can lead to enhanced sensitivity to unrelated drugs. This phenomenon of collateral sensitivity is largely unexplored in
M. tuberculosis
but has the potential to identify alternative therapeutic strategies to combat drug-resistant strains that are unresponsive to current treatments. Here, by using drug susceptibility profiling, genomics and evolutionary studies we provide evidence for the existence of collateral drug sensitivities in an isogenic collection
M. tuberculosis
drug-resistant strains. Furthermore, in proof-of-concept studies, we demonstrate how collateral drug phenotypes can be exploited to select against and prevent the emergence of drug-resistant strains. This study highlights that the evolution of drug resistance in
M. tuberculosis
leads to collateral drug responses that can be exploited to design improved drug regimens.
Here using drug susceptibility profiling, genomics and evolutionary studies the authors provide strategies to exploit collateral drug responses in
Mycobacterium tuberculosis
to prevent the emergence of drug resistance.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
